# Secura Bio

Secura Bio is an Asset Manager based in Berkeley Heights, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Berkeley Heights, United States
- **Region:** North America
- **Address:** Berkeley Heights, New Jersey, United States
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** securabio.com
- **LinkedIn:** https://www.linkedin.com/company/securabio

## Regulatory record

- **Reports private funds:** No

## About

Secura Bio is a biopharmaceutical company based in Mesa, United States, founded in 2019. It has secured $55 million in total funding. The company operates as an integrated biopharmaceutical entity.

## Sectors

- Biotechnology
- Pharmaceuticals
- Oncology
- Hematology

## Offices

- Dublin, Ireland
- Las Vegas, United States

## People

- Juan Estruch — Co-Founder
- Chip R. Romp — Executive Vice President, US Commercial (former Seagen)
- Will Brown — Chief Financial Officer
- Gregory S. Wessels — Chief Commercial Officer
- Christiane Langer — Senior Vice President, Global Medical Affairs
- Cari Barthe — Director of People and Culture
- Patrick Vink — Chairman of the Board
- Jeffrey A. Ferrell — Board Member
- Joerg Moeller — Board Member

## Questions

### Who started Secura Bio and what is the background of its leadership?

The firm was co-founded in 2019 by Juan Estruch, who has over 25 years in life sciences corporate development at Novartis, Ciba-Geigy, and Genoptix. The board is chaired by Patrick Vink, former COO of Cubist, and includes Jeffrey A. Ferrell, founder of Athyrium Capital Management (per the firm's website).

### How does Secura Bio differ from a traditional pharmaceutical company?

Secura Bio does not invest in early-stage drug discovery. Instead, it acquires or licenses approved or late-stage oncology therapies and applies a specialized commercial team to maximize their market potential. This operating-company model sits between a pharmaceutical company and an investment firm.

### Does Secura Bio disclose its AUM or investment returns?

The firm does not publicly disclose AUM, deployment size, or portfolio returns. Its website focuses on the team's track record at prior companies rather than its own capital base (per firm website, 2025).

## Related profiles

- [SDX](https://altss.com/profile/sdx)
- [Duopharma Biotech Berhad](https://altss.com/profile/duopharma-biotech-berhad)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/secura-bio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology